From Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins:

nyhavn-picture-id843803566

nyhavn-picture-id843803566—

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Xconomy on Demand

We offer a number of ways to subscribe for free!